Heron Therapeutics INC (HRTX) Shareholder Cam Group Holding A Raised Its Stake by $3.69 Million

Cam Group Holding A increased its stake in Heron Therapeutics Inc (HRTX) by 85.08% based on its latest 2018Q2 regulatory filing with the SEC. Cam Group Holding A bought 97,002 shares as the company’s stock rose 17.28% with the market. The institutional investor held 211,012 shares of the health care company at the end of 2018Q2, valued at $8.20M, up from 114,010 at the end of the previous reported quarter. Cam Group Holding A who had been investing in Heron Therapeutics Inc for a number of months, seems to be bullish on the $2.21B market cap company. The stock increased 1.72% or $0.48 during the last trading session, reaching $28.36. About 479,004 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 132.23% since December 6, 2017 and is uptrending. It has outperformed by 116.61% the S&P500.

Cam Group Holding A, which manages about $7.21B US Long portfolio, decreased its stake in Home Depot Inc (NYSE:HD) by 49,654 shares to 3.04M shares, valued at $593.70M in 2018Q2, according to the filing. It also reduced its holding in Citigroup Inc (NYSE:C) by 66,911 shares in the quarter, leaving it with 6.62M shares, and cut its stake in Alphabet Inc.

More notable recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron Therapeutics: Disrupting The Standard Of Care In Pain Management – Seeking Alpha” on June 08, 2018, also Streetinsider.com with their article: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” published on November 14, 2018, Globenewswire.com published: “Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on November 27, 2018. More interesting news about Heron Therapeutics, Inc. (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “Heron Therapeutics Can Still Rally – Seeking Alpha” published on March 22, 2018 as well as Nasdaq.com‘s news article titled: “Heron Therapeutics (HRTX) Q3 Earnings Preview: What to Expect – Nasdaq” with publication date: October 29, 2018.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Coverage

Among 6 analysts covering Heron Therapeutics (NASDAQ:HRTX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 6 analyst reports since June 21, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Oppenheimer given on Friday, June 22. As per Thursday, June 21, the company rating was maintained by Mizuho. The firm has “Overweight” rating given on Thursday, July 19 by Cantor Fitzgerald. Leerink Swann maintained the shares of HRTX in report on Friday, June 22 with “Buy” rating. Evercore maintained it with “Outperform” rating and $80 target in Thursday, June 21 report.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.